Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Konstantinos Giannitsas & Anastasios Athanasopoulos. (2015) A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?. Expert Review of Pharmacoeconomics & Outcomes Research 15:3, pages 413-423.
Read now
Read now
Warren Mark Hart, Paul Abrams, Vicki Munro, Peny Retsa & Jameel Nazir. (2013) Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom. Journal of Medical Economics 16:10, pages 1246-1254.
Read now
Read now
S. Herschorn, P. Pommerville, L. Stothers, B. Egerdie, J. Gajewski, K. Carlson, S. Radomski, H. Drutz, J. Schulz, J. Barkin, E. Hirshberg & J. Corcos. (2011) Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Current Medical Research and Opinion 27:2, pages 375-382.
Read now
Read now
Articles from other publishers (6)
Yuriko Yamanishi, Tomonori Yamanishi, Hakujyu Tajima & Shunya Ikeda. (2018) Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost‐effective as the first‐line treatment?. International Journal of Urology 25:10, pages 863-870.
Crossref
Crossref
Sonya J. Snedecor. (2018) Review of Economic Value Drivers of the Treatment of Overactive Bladder. PharmacoEconomics 36:9, pages 1083-1092.
Crossref
Crossref
Xavier Biardeau, Lysanne Campeau & Jacques Corcos. (2017) We should not use oxybutynin chloride in OAB. Neurourology and Urodynamics 36:3, pages 822-823.
Crossref
Crossref
Suneetha Rachaneni, Shanteela McCooty, Lee J Middleton, Victoria L Parker, Jane P Daniels, Arri Coomarasamy, Tina S Verghese, Moji Balogun, Ilias Goranitis, Pelham Barton, Tracy E Roberts, Jonathan J Deeks & Pallavi Latthe. (2016) Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technology Assessment 20:7, pages 1-150.
Crossref
Crossref
W. Gibson, A. Athanasopoulos, H. Goldman, H. Madersbacher, D. Newman, J. Spinks, J. J. Wyndaele & A. Wagg. (2014) Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?. International Journal of Clinical Practice 68:9, pages 1165-1173.
Crossref
Crossref
Stefan Vegter, Keith Tolley, Michael S. Keith, Charmaine E. Lok, Steven D. Soroka & A. Ross Morton. (2012) Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective. Clinical Therapeutics 34:7, pages 1531-1543.
Crossref
Crossref